NEW YORK, Feb 26 – Pharmacopeia of Princeton, NJ, said Monday it would combine its four life science software units into a single entity, effective June 1.
“We’ve been acquiring different software businesses all related to drug discovery and chemical development, so we’re going to continue doing what we do, which is design and sell software to help our customers discover drugs and develop chemicals, but now we’ll just do it under one name since all the products are basically related,” Sue Rodney, manager of investor relations at Pharmacopeia, told GenomeWeb.
Rodney did not comment on whether merging the business units would result in layoffs.
The new software business will incorporate Molecular Simulations, Genetics Computer Group, Oxford Molecular Group, and Synopsys Scientific Systems. The software unit, for which a name has been chosen but not disclosed, will be based in San Diego and Cambridge, UK.
Michael Stapleton, who was recently promoted to chief operating officer of Pharmacopeia’s software business, will head the new organization.
An official announcement of the new unit will take place at the American Chemical Society Meeting in San Diego April 1-5.